Literature DB >> 16466325

Optimizing antibiotic treatment for ventilator-associated pneumonia.

Scott T Micek1, Timothy J Heuring, James M Hollands, Rina A Shah, Marin H Kollef.   

Abstract

Ventilator-associated pneumonia (VAP) is the most common infectious complication in patients receiving mechanical ventilation and accounts for exorbitant use of resources in the intensive care unit. Antimicrobial management of VAP incorporates an initial broad-spectrum, empiric regimen to ensure appropriate coverage with deescalation of therapy after 48-72 hours based on culture results and sensitivities. When VAP clinically responds to treatment, antimicrobials should be discontinued after 7-8 days to reduce overall antibiotic consumption and the selection pressure on flora observed in the intensive care unit and thus minimize the development and spread of antimicrobial resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466325     DOI: 10.1592/phco.26.2.204

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

1.  [Antibiotic treatment of surgical intensive care patients: procalcitonin to guide duration of therapy].

Authors:  M Hochreiter; T Köhler; A-M Schweiger; F S Keck; B Bein; T von Spiegel; S Schröder
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

2.  Rapid automated microscopy for microbiological surveillance of ventilator-associated pneumonia.

Authors:  Ivor S Douglas; Connie S Price; Katherine H Overdier; Robert F Wolken; Steven W Metzger; Kenneth R Hance; David C Howson
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 21.405

3.  Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Authors:  P Prokocimer; P Bien; J Surber; P Mehra; C DeAnda; J B Bulitta; G R Corey
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

4.  Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.

Authors:  S Schroeder; M Hochreiter; T Koehler; A-M Schweiger; B Bein; F S Keck; T von Spiegel
Journal:  Langenbecks Arch Surg       Date:  2008-11-26       Impact factor: 3.445

Review 5.  Multiresistant bacteria and current therapy - the economical side of the story.

Authors:  Michael H Wilke
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

6.  Factors Associated with Mortality in Immunocompetent Patients with Hospital-acquired Pneumonia.

Authors:  Pavaruch Sangmuang; Aroonrut Lucksiri; Wasan Katip
Journal:  J Glob Infect Dis       Date:  2019 Jan-Mar

7.  Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial.

Authors:  Marcel Hochreiter; Thomas Köhler; Anna Maria Schweiger; Fritz Sixtus Keck; Berthold Bein; Tilman von Spiegel; Stefan Schroeder
Journal:  Crit Care       Date:  2009-06-03       Impact factor: 9.097

8.  Antibiotic Utilization Patterns in Patients with Ventilator-Associated Pneumonia: A Canadian Context.

Authors:  Tracy Chin; Barry Kushner; Deonne Dersch-Mills; Danny J Zuege
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-07-20       Impact factor: 2.471

9.  Management of ventilator-associated pneumonia in intensive care units: a mixed methods study assessing barriers and facilitators to guideline adherence.

Authors:  Nasia Safdar; Jackson S Musuuza; Anping Xie; Ann Schoofs Hundt; Matthew Hall; Kenneth Wood; Pascale Carayon
Journal:  BMC Infect Dis       Date:  2016-07-22       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.